10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

News
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 62

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Background/Significance

Large language models such as ChatGPT are increasingly used by patients to understand radiology reports. Studies have demonstrated that most patients have an 8th grade reading comprehension level. Readability metrics can assess whether radiology reports are close to a patient’s level of understanding. Our study aimed to evaluate whether ChatGPT model 4 could improve readability of breast imaging reporting and data system (BI-RADS) categories 3, 4, and 5 reports while maintaining accuracy.

Materials and Methods

Fifteen consecutive BI-RADS 3, BI-RADS 4, and BI-RADS 5 source reports were retrieved from the radiology database. ChatGPT prompts were given as follows: “please put the report into layperson terms” and “please provide recommendations for the patient.” ChatGPT prompts generated layperson reports and recommendations for all 45 source reports.

Readability of source reports, layperson reports, and layperson recommendations were analyzed for each BI-RADS category using Flesch-Kincaid readability score in grade level and word counts. Flesch-Kincaid score is an established tool used to assess health literacy. Grade level scores define the reading comprehension grade level. High word count is associated poorer readability. A radiologist evaluated the accuracy of ChatGPT-generated outputs by identifying inaccurate/misleading information and whether the layperson reports contained beneficial supplementary information not found in the original report. Statistical analysis was performed using 2-sided unpaired, equal-variance t-tests.

Results

Statistically significant decrease in mean grade level was identified for BI-RADS 3 source vs layperson reports (mean grade level, 10.9; SD = 1.8; vs mean grade level, 8.8; SD = 1.0; P = .003), and for BI-RADS 5 source vs layperson reports (mean grade level, 12.2; SD, 3.0; vs mean grade level, 9.6; SD = 0.8; P = .003). No statistical difference was seen in grade level between source reports and ChatGPT-generated recommendations for all 3 BI-RADS categories (Table 1).

Table 1. Mean Grade Level Scores With Accompanying Standard Deviations in Parentheses of Source Reports, ChatGPT-Generated Layperson Reports, and Recommendations for Each BI-RADS Category

Table 1. Mean Grade Level Scores With Accompanying Standard Deviations in Parentheses of Source Reports, ChatGPT-Generated Layperson Reports, and Recommendations for Each BI-RADS Category

There was a statistically significant decreased word count for BI-RADS 3 and BI-RADS 4 source vs ChatGPT-generated recommendations (P = .001 and P = .02, respectively). No statistically significant difference was observed between word count of source and layperson reports for all 3 BI-RADS categories.

ChatGPT-generated reports did not contain inaccurate or misleading information; however, the reports did offer beneficial supplementary information, particularly in terms of biopsy recommendations, compared with source reports.

Conclusion

ChatGPT improved readability (grade level) for BI-RADS 3 and 5 reports, and produced less wordy recommendations for BI-RADS 3 and 4 reports. ChatGPT-generated reports did not contain inaccurate information that would affect patient management. ChatGPT could be used to generate patient-friendly reports, which could potentially lessen patient anxiety surrounding breast imaging.

Articles in this issue

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC
TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC
TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content